Lymphoma & CLL Therapeutics

Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was delighted to...

ZUMA-1 | Should age limit the use of axicabtagene ciloleucel?

Results from a post-hoc analysis of the two-year results of ZUMA-1, by age ( < 65 vs ≥ 65 years).

KEYNOTE-204: Pembrolizumab versus brentuximab vedotin R/R classic Hodgkin lymphoma

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was pleased to speak to John...

Nivolumab plus AVD as first-line treatment for high-risk classic Hodgkin lymphoma

Paul J. Bröckelmann and colleagues conducted the open-label, multicenter, randomized, phase II NIVAHL study...

FDA grants CLR 131 fast track designation for the treatment of patients with lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia

On May 26, 2020, CLR 131, a radiotherapeutic phospholipid drug...

FDA grants CLR 131 Orphan Drug designation in lymphoplasmacytic lymphoma

On the 6th January 2020, CLR 131, an investigational small-molecule radio-therapeutic, was granted Orphan Drug Designation by...

Positive interim results announced for TRPH-222 in patients with NHL

On May 18, 2020, positive interim results were announced from the multi-center, open-label, phase I study of TRPH-222...

(177)Lu lilotomab satetraxetan receives positive opinion for orphan drug designation from EMA for MZL

On May 14, 2020, (177)Lu lilotomab satetraxetan received a positive opinion from the European...